^
Association details:
| Biomarker: | CDKN2A overexpression |
|---|---|
| Cancer: | Mantle Cell Lymphoma |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib Synergizes with BCL2 Inhibitor Venetoclax in Experimental Models of Chemotherapy Refractory Mantle Cell Lymphoma
Published date:
11/04/2021
Excerpt:
Of note, overexpression of MYC and CDKN2A K/O both increased sensitivity to venetoclax.
DOI:
10.1182/blood-2021-150517
